Article Text

Download PDFPDF
Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In black or non-black patients with hypertension, is amlodipine or lisinopril better than chlorthalidone for reducing cardiovascular disease (CVD)?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Cardiology ★★★★★★☆


Embedded ImageDesign:

randomised controlled trial (Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {clinicians, patients, data collectors, outcome assessors, and steering committee}.*

Embedded ImageFollow up period:

mean 4.9 years.

Embedded ImageSetting:

623 centres in the US, Canada, Puerto Rico, and the US Virgin Islands.

Embedded ImagePatients:

33 357 black and non-black patients ⩾55 years of age (mean age 67 y, 35% black, 53% men overall, 54% women among blacks) who had hypertension with ⩾1 additional risk factor for coronary heart disease (CHD), including left ventricular [LV] hypertrophy, type 2 diabetes, current smoker, high density lipoprotein cholesterol concentration <0.9 mmol/l (35 mg/dl), and myocardial infarction (MI) …

View Full Text


  • * See glossary.

  • The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  • For correspondence: Dr J T Wright Jr, Case Western Reserve University, Cleveland, OH, USA. jackson.wright{at}

  • Source of funding: National Heart, Lung, and Blood Institute.